Research Article
BibTex RIS Cite

VİTİLİGO TANILI HASTALARDA İNTERFERON-GAMMA/ İNTERLÖKİN-10 ORANININ HASTALIK AKTİVİTESİ VE YAYGINLIĞI İLE İLİŞKİSİ The Relationship Between Interferon-gamma / Interleukin-10 Rate with Disease Activity and Enlargement in Vitiligo Patients

Year 2020, Volume: 10 Issue: 1, 217 - 226, 25.03.2020

Abstract

ÖZET
Amaç: Bu çalışmada vitiligolu hastaların serumlarında proinflamatuvar karakterde olan interferon-gamma
(IFN-γ) ve antiinflamatuvar karakterde olan interlökin (IL)-10 seviyeleri ve bu sitokinlerin birbiriyle olan oranı;
bunların hastalığın yaygınlığı ve aktivitesi ile ilişkili olup olmadığını araştırmak amaçlanmıştır.
Gereç ve Yöntem: Çalışmaya klinik olarak vitiligo tanısı konulan 42 hasta ve 42 kontrol alındı. Serum IFN-γ, IL-
10, antinükleer antikor (ANA), C-reaktif protein (CRP) seviyeleri ölçüldü; vitiligo alan şiddet indeksi (VASI) ve
vitiligo hastalık aktivite skoru (VIDA) değerleri hesaplandı ve uygun istatiksel analizler yapıldı.
Bulgular: Hasta ve kontrol grubu arasında IFN-γ, IL-10, ANA, CRP seviyeleri ve IFN-γ / IL-10 oranı açısından anlamlı
fark bulunmadı. VASI > 200 (yaygın tutulumlu hastalar) olan hastalarla, kontrol grubu karşılaştırıldığında
IL-10 değerleri arasında anlamlı farklılık saptandı (p= 0,02). VIDA > 2 (son 6 ayda yeni lezyon çıkışı olan, aktif
hastalar) hastalarda IL-10 seviyeleri arasında yapılan korelasyon analizinde serum IL-10 değerinin pozitif yönde
etkilendiği gözlendi (p= 0,028; r= 0,656). Hastalık süresinin IL-10 üzerine etkisi olup olmadığı değerlendirildiğinde
korelasyon saptandı (p= 0,034). Bu korelasyonun negatif yönde orta derecede ilişkili olduğu saptandı
(r = -0,502). IFN-γ / IL-10 oranı VASI > 200 olan hastalar ile VIDA > 2 olan hastalarda kontrole kıyasla anlamlı
derecede yüksek bulundu (p= 0,04; p= 0,018).
Sonuç: Çalışmamızda en çok dikkat çeken sonuç, IL-10 seviyesinin hastalığın aktif döneminde ve yaygın tutulumu
olan hastalarda anlamlı derecede yüksek bulunmasıydı. Bu çalışma, yüksek sitokin seviyelerinin, melanosit
hasarının daha geniş alanlarda gözlenmesinin nedeni olduğunu ve vitiligo patogenezinde otoimmün sürecin
önemli derecede katkısı olduğunu göstermiştir.
Anahtar kelimeler: Vitiligo ; Gama- interferon ; İnterlökin-10
ABSTRACT
Aim: The aim of this study is to investigate whether the levels of interferon-gamma (IFN-γ) which have proinflammatory
character, interleukin (IL)-10 which have antiinflamatory character and the ratio of these cytokines
with each other are related to the prevalence and activity of the disease.
Materials and Methods: The study included 42 patients with clinically diagnosed vitiligo and 42 controls.
Serum IFN-γ, IL-10, antinuclear antibody (ANA), C-reactive protein (CRP) levels were measured; vitiligo area
severity index (VASI) and vitiligo disease activity score (VIDA) were calculated and appropriate statistical analyzes
were performed.
Results: There was no significant difference between the patient and control groups in terms of IFN-γ, IL-10,
ANA, CRP levels and IFN-γ / IL-10 ratio. There was a significant difference between IL-10 values in patients
with VASI > 200 (patients with diffuse involvement) and control group (p = 0,02). In the correlation analysis
between IL-10 levels in VIDA > 2 (active patients with new lesion emergence in the last 6 months), a positive
effect of serum IL-10 value was observed (p = 0,028; r = 0,656). There was a correlation between the duration
of disease and IL-10 (p = 0,034). This correlation was found to be moderately correlated negatively (r = -0,502).
IFN-γ / IL-10 ratio was significantly higher in patients with VASI > 200 and patients with VIDA > 2 compared to
control (p = 0,04; p = 0,018).
Conclusion: The most striking result in our study was that IL-10 levels were significantly higher in patients with
active involvement and widespread involvement. This study demonstrated that high cytokine levels are the
cause of melanocyte damage observed in larger areas and that autoimmune processes contribute significantly
to the pathogenesis of vitiligo.
Key words: Vitiligo; Gama-interferon ; Interleukin-10

References

  • 1. Ortonne JP, Bahadoran P, Fitzpatrick TB. Hypomelanoses and hypermelanoses. Fitzpatrick’s Dermatology in General Medicine. Ed. Freedberg IM, Eisen AZ, Wolf K, USA, McGraw-Hill, 2003; 836-881. 2. Arıcan Ö, Koç K, Kutluk R, Ersoy L. Vitiligolu hastalarda serum vitamin B12 ve folik asit düzeyleri. Türkiye Klinikleri Dermatoloji 2003; 13: 4-10. 3. Rebat M, Sumayah J. Vitiligo. In: Fitzpatrick, ed. Fitzpatrick’s Dermatology in General Medicine. New York: McGraw Hill 2008 ;616–22. 4. Aksungur V, Tüzün Y, Gürer MA, Serdaroğlu S, Oğ uz O. Dermatoloji 1-2. 3.baskı; İ stanbul: Nobel Tıp Kitapevleri 2008;1465–73. 5. Ala Y, Pasha MK, Rao RN et al. Association of IFN-y}: IL-10 Cytokine Ratio with Nonsegmental Vitiligo Pathogenesis. Hindawi Publishing Corporation Autoimmune Diseases 2015. doi; 42349010.1155/2015/42349. 6. Dwivedi M, Laddha NC, Shah K et al. Involvement of Interferon-Gamma Genetic Variants and Intercellular Adhesion Molecule-1 in Onset and Progression of Generalized Vitiligo. Journal of Interferon & cytokıne research, Volume 33, Number 11, 2013. doi: 10.1089/jir.2012.0171 7. Singh S et al, Serum concentration of IL-6, IL-2, TNF-α, and IFNγ in Vitiligo patients. Indian J Dermatol. 2012 Jan-Feb; 57(1): 12–1. doi: 10.4103/0019-5154.9266 8. Tembhre MJ, Sharma VK, Sharma A, Chattopadhyay P, Gupta S. T helper and regulatory T cell cytokine profile in active, stable and narrow band ultraviolet B treated generalized vitiligo. Clinica Chimica Acta; International Journal of Clinical Chemistry, 13 May 2013, 424:27-32. doi: 10.1016/j.cca.2013.05.005 9. Mitra S, De Sarkar S, Pradhan A, Pati AK, Pradhan R, Mondal D, Sen S, Ghosh A, Chatterjee S, Chatterjee M., Levels of oxidative damage and proinflammatory cytokines are enhanced in patients with active vitiligo. 2017 Dec;51(11-12):986-994. doi: 10.1080/10715762.2017.1402303. 10. Yang L, Weı Y, Sun Y, Shi W, Yang J, Zhu L, Lı M, Interferon-gamma Inhibits Melanogenesis and Induces Apoptosis in Melanocytes: A Pivotal Role of CD8+ Cytotoxic T Lymphocytes in Vitiligo, Acta Derm Venereol 2015; 95: 664–670. doi: 10.2340/00015555-2080
Year 2020, Volume: 10 Issue: 1, 217 - 226, 25.03.2020

Abstract

References

  • 1. Ortonne JP, Bahadoran P, Fitzpatrick TB. Hypomelanoses and hypermelanoses. Fitzpatrick’s Dermatology in General Medicine. Ed. Freedberg IM, Eisen AZ, Wolf K, USA, McGraw-Hill, 2003; 836-881. 2. Arıcan Ö, Koç K, Kutluk R, Ersoy L. Vitiligolu hastalarda serum vitamin B12 ve folik asit düzeyleri. Türkiye Klinikleri Dermatoloji 2003; 13: 4-10. 3. Rebat M, Sumayah J. Vitiligo. In: Fitzpatrick, ed. Fitzpatrick’s Dermatology in General Medicine. New York: McGraw Hill 2008 ;616–22. 4. Aksungur V, Tüzün Y, Gürer MA, Serdaroğlu S, Oğ uz O. Dermatoloji 1-2. 3.baskı; İ stanbul: Nobel Tıp Kitapevleri 2008;1465–73. 5. Ala Y, Pasha MK, Rao RN et al. Association of IFN-y}: IL-10 Cytokine Ratio with Nonsegmental Vitiligo Pathogenesis. Hindawi Publishing Corporation Autoimmune Diseases 2015. doi; 42349010.1155/2015/42349. 6. Dwivedi M, Laddha NC, Shah K et al. Involvement of Interferon-Gamma Genetic Variants and Intercellular Adhesion Molecule-1 in Onset and Progression of Generalized Vitiligo. Journal of Interferon & cytokıne research, Volume 33, Number 11, 2013. doi: 10.1089/jir.2012.0171 7. Singh S et al, Serum concentration of IL-6, IL-2, TNF-α, and IFNγ in Vitiligo patients. Indian J Dermatol. 2012 Jan-Feb; 57(1): 12–1. doi: 10.4103/0019-5154.9266 8. Tembhre MJ, Sharma VK, Sharma A, Chattopadhyay P, Gupta S. T helper and regulatory T cell cytokine profile in active, stable and narrow band ultraviolet B treated generalized vitiligo. Clinica Chimica Acta; International Journal of Clinical Chemistry, 13 May 2013, 424:27-32. doi: 10.1016/j.cca.2013.05.005 9. Mitra S, De Sarkar S, Pradhan A, Pati AK, Pradhan R, Mondal D, Sen S, Ghosh A, Chatterjee S, Chatterjee M., Levels of oxidative damage and proinflammatory cytokines are enhanced in patients with active vitiligo. 2017 Dec;51(11-12):986-994. doi: 10.1080/10715762.2017.1402303. 10. Yang L, Weı Y, Sun Y, Shi W, Yang J, Zhu L, Lı M, Interferon-gamma Inhibits Melanogenesis and Induces Apoptosis in Melanocytes: A Pivotal Role of CD8+ Cytotoxic T Lymphocytes in Vitiligo, Acta Derm Venereol 2015; 95: 664–670. doi: 10.2340/00015555-2080
There are 1 citations in total.

Details

Primary Language Turkish
Subjects Health Care Administration
Journal Section Original Research
Authors

Gözde Emel Gökçek This is me

Eda Öksüm Solak This is me

Demet Kartal This is me

Murat Borlu This is me

Salih Levent Çınar This is me

Publication Date March 25, 2020
Published in Issue Year 2020 Volume: 10 Issue: 1

Cite

APA Gökçek, G. E., Öksüm Solak, E., Kartal, D., Borlu, M., et al. (2020). VİTİLİGO TANILI HASTALARDA İNTERFERON-GAMMA/ İNTERLÖKİN-10 ORANININ HASTALIK AKTİVİTESİ VE YAYGINLIĞI İLE İLİŞKİSİ The Relationship Between Interferon-gamma / Interleukin-10 Rate with Disease Activity and Enlargement in Vitiligo Patients. Bozok Tıp Dergisi, 10(1), 217-226.
AMA Gökçek GE, Öksüm Solak E, Kartal D, Borlu M, Çınar SL. VİTİLİGO TANILI HASTALARDA İNTERFERON-GAMMA/ İNTERLÖKİN-10 ORANININ HASTALIK AKTİVİTESİ VE YAYGINLIĞI İLE İLİŞKİSİ The Relationship Between Interferon-gamma / Interleukin-10 Rate with Disease Activity and Enlargement in Vitiligo Patients. Bozok Tıp Dergisi. March 2020;10(1):217-226.
Chicago Gökçek, Gözde Emel, Eda Öksüm Solak, Demet Kartal, Murat Borlu, and Salih Levent Çınar. “VİTİLİGO TANILI HASTALARDA İNTERFERON-GAMMA/ İNTERLÖKİN-10 ORANININ HASTALIK AKTİVİTESİ VE YAYGINLIĞI İLE İLİŞKİSİ The Relationship Between Interferon-Gamma / Interleukin-10 Rate With Disease Activity and Enlargement in Vitiligo Patients”. Bozok Tıp Dergisi 10, no. 1 (March 2020): 217-26.
EndNote Gökçek GE, Öksüm Solak E, Kartal D, Borlu M, Çınar SL (March 1, 2020) VİTİLİGO TANILI HASTALARDA İNTERFERON-GAMMA/ İNTERLÖKİN-10 ORANININ HASTALIK AKTİVİTESİ VE YAYGINLIĞI İLE İLİŞKİSİ The Relationship Between Interferon-gamma / Interleukin-10 Rate with Disease Activity and Enlargement in Vitiligo Patients. Bozok Tıp Dergisi 10 1 217–226.
IEEE G. E. Gökçek, E. Öksüm Solak, D. Kartal, M. Borlu, and S. L. Çınar, “VİTİLİGO TANILI HASTALARDA İNTERFERON-GAMMA/ İNTERLÖKİN-10 ORANININ HASTALIK AKTİVİTESİ VE YAYGINLIĞI İLE İLİŞKİSİ The Relationship Between Interferon-gamma / Interleukin-10 Rate with Disease Activity and Enlargement in Vitiligo Patients”, Bozok Tıp Dergisi, vol. 10, no. 1, pp. 217–226, 2020.
ISNAD Gökçek, Gözde Emel et al. “VİTİLİGO TANILI HASTALARDA İNTERFERON-GAMMA/ İNTERLÖKİN-10 ORANININ HASTALIK AKTİVİTESİ VE YAYGINLIĞI İLE İLİŞKİSİ The Relationship Between Interferon-Gamma / Interleukin-10 Rate With Disease Activity and Enlargement in Vitiligo Patients”. Bozok Tıp Dergisi 10/1 (March 2020), 217-226.
JAMA Gökçek GE, Öksüm Solak E, Kartal D, Borlu M, Çınar SL. VİTİLİGO TANILI HASTALARDA İNTERFERON-GAMMA/ İNTERLÖKİN-10 ORANININ HASTALIK AKTİVİTESİ VE YAYGINLIĞI İLE İLİŞKİSİ The Relationship Between Interferon-gamma / Interleukin-10 Rate with Disease Activity and Enlargement in Vitiligo Patients. Bozok Tıp Dergisi. 2020;10:217–226.
MLA Gökçek, Gözde Emel et al. “VİTİLİGO TANILI HASTALARDA İNTERFERON-GAMMA/ İNTERLÖKİN-10 ORANININ HASTALIK AKTİVİTESİ VE YAYGINLIĞI İLE İLİŞKİSİ The Relationship Between Interferon-Gamma / Interleukin-10 Rate With Disease Activity and Enlargement in Vitiligo Patients”. Bozok Tıp Dergisi, vol. 10, no. 1, 2020, pp. 217-26.
Vancouver Gökçek GE, Öksüm Solak E, Kartal D, Borlu M, Çınar SL. VİTİLİGO TANILI HASTALARDA İNTERFERON-GAMMA/ İNTERLÖKİN-10 ORANININ HASTALIK AKTİVİTESİ VE YAYGINLIĞI İLE İLİŞKİSİ The Relationship Between Interferon-gamma / Interleukin-10 Rate with Disease Activity and Enlargement in Vitiligo Patients. Bozok Tıp Dergisi. 2020;10(1):217-26.
Copyright © BOZOK Üniversitesi - Tıp Fakültesi